MedPath

M.D. ANDERSON CANCER CENTER

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

Not Applicable
Recruiting
Conditions
Liver
Interventions
Behavioral: Questionnaires
First Posted Date
2023-05-30
Last Posted Date
2024-11-05
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
36
Registration Number
NCT05879159
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Phase 2
Withdrawn
Conditions
Recurrent Glioblastoma
Interventions
Drug: Pembrolizumab
Device: Exablate MRgFUS + neoadjuvant pembolizumab
First Posted Date
2023-05-30
Last Posted Date
2024-11-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
10
Registration Number
NCT05879120
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

Phase 2
Active, not recruiting
Conditions
Tumor
Interventions
First Posted Date
2023-05-30
Last Posted Date
2024-12-17
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT05879146
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Phase 2
Not yet recruiting
Conditions
Prostate Cancer
Interventions
First Posted Date
2023-05-24
Last Posted Date
2024-08-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT05873192
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients with Pancreatic Cysts Undergoing Surgical Resection

Phase 1
Active, not recruiting
Conditions
Pancreatic Cyst
Interventions
Drug: Hyperpolarized 13-C-pyruvate
First Posted Date
2023-05-24
Last Posted Date
2024-12-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
10
Registration Number
NCT05873699
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Phase 1
Recruiting
Conditions
Ovarian Cancer
Interventions
Drug: Hyperpolarized 13-C-pyruvate
First Posted Date
2023-05-19
Last Posted Date
2024-10-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT05866679
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Phase 1
Withdrawn
Conditions
Lung Cancer
Gastro-intestinal Cancer
Interventions
First Posted Date
2023-05-08
Last Posted Date
2024-01-23
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT05848843
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Early Phase 1
Not yet recruiting
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Drug: Control Group
Drug: TTI-101
First Posted Date
2023-05-06
Last Posted Date
2024-05-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
33
Registration Number
NCT05845307
Locations
🇺🇸

M D Anderson Cancer Centerl, Houston, Texas, United States

Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance

Active, not recruiting
Conditions
Prostate Cancer
Interventions
Other: Active Surveillance
First Posted Date
2023-05-03
Last Posted Date
2024-08-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
17
Registration Number
NCT05840484
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer

Recruiting
Conditions
Penile Cancer
Interventions
Behavioral: Quality of Life Questionnaires
Behavioral: Patient Educational Needs
Behavioral: Symptom Management
First Posted Date
2023-05-03
Last Posted Date
2024-03-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT05842031
Locations
🇺🇸

MD Anderson, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath